Dr. Lataillade ViiV date:
VH3810109 (N6LS) in Antiretroviral Therapy
Naive Adults With HIV-1: Phase 2a BANNER
Efficacy Data:
Peter Leone,1 Alejandro Ferro,2 Sergio Lupo,3 Joseph McGowan,4 Paul Benson,5 Marisa Sanchez,6
Stefan Schneider,7 Paul Wannamaker,1 Beta Win,8 Judah Abberbock,9 Viviana Wilches,9 Margaret Gartland,1 Max Lataillade,10 Jan Losos1
1ViiV Healthcare, Durham, NC, USA; 2Centro de Investigaciones Medicas, Mar del Plata, Argentina; 3CAICI, Rosario, Argentina;
4Northwell Health, New York, NY, USA; 5Be Well Medical Center, Berkley, MI, USA; 6Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina; 7Long Beach Education and Research Consultants, Long Beach, CA, USA; 8GSK, Brentford, UK; 9GSK, Collegeville, PA, USA;
10ViiV Healthcare, Branford, CT, USA
Conference on Retroviruses and Opportunistic Infections;
March 3-6, 2024; Denver, CO
Bottom of presentation Acknowledgments:
• We thank the study participants, their families and caregivers, the investigators and site staff who
participated in the study, and the ViiV Healthcare and GSK study team members
___
3 ways this March 2024 presentation refers to Dr. Lataillade as ViiV employed.
Can't see him within 5 months later, deciding, for fun, let me give up for the hell of it:
* stable home life
* corporate jets
* skybox @ sports
* best healthcare
* free company car
* company bonuses
Tyler's was talked about, imagine Dr. Lataillade's
* access to ViivV, GSK, Pfizer
& go join Cytodyn.
Who's only plan for raising 2024 funds was re-pricing warrants & considering an Amarex settlement.
With less than the "as of August" $24m in cash, @ the time he was hired just days ago.
The science & and patents are unprecedented @ Cytodyn.
VH3810109 (N6LS) in Antiretroviral Therapy
Naive Adults With HIV-1: Phase 2a BANNER
Efficacy Data:
Peter Leone,1 Alejandro Ferro,2 Sergio Lupo,3 Joseph McGowan,4 Paul Benson,5 Marisa Sanchez,6
Stefan Schneider,7 Paul Wannamaker,1 Beta Win,8 Judah Abberbock,9 Viviana Wilches,9 Margaret Gartland,1 Max Lataillade,10 Jan Losos1
1ViiV Healthcare, Durham, NC, USA; 2Centro de Investigaciones Medicas, Mar del Plata, Argentina; 3CAICI, Rosario, Argentina;
4Northwell Health, New York, NY, USA; 5Be Well Medical Center, Berkley, MI, USA; 6Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina; 7Long Beach Education and Research Consultants, Long Beach, CA, USA; 8GSK, Brentford, UK; 9GSK, Collegeville, PA, USA;
10ViiV Healthcare, Branford, CT, USA
Conference on Retroviruses and Opportunistic Infections;
March 3-6, 2024; Denver, CO
Bottom of presentation Acknowledgments:
• We thank the study participants, their families and caregivers, the investigators and site staff who
participated in the study, and the ViiV Healthcare and GSK study team members
___
3 ways this March 2024 presentation refers to Dr. Lataillade as ViiV employed.
Can't see him within 5 months later, deciding, for fun, let me give up for the hell of it:
* stable home life
* corporate jets
* skybox @ sports
* best healthcare
* free company car
* company bonuses
Tyler's was talked about, imagine Dr. Lataillade's
* access to ViivV, GSK, Pfizer
& go join Cytodyn.
Who's only plan for raising 2024 funds was re-pricing warrants & considering an Amarex settlement.
With less than the "as of August" $24m in cash, @ the time he was hired just days ago.
The science & and patents are unprecedented @ Cytodyn.
6
